carbon monoxide has been researched along with Graft vs Host Disease in 3 studies
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.
Graft vs Host Disease: The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In multivariate analysis, chronic graft-versus-host disease (relative risk, 16) and pretransplantation diffusion capacity for carbon monoxide or forced expiratory volume in the first second <80% predicted were independently associated with a late decrease in PF from baseline (relative risk, 7)." | 3.73 | Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. ( Barrett, AJ; Childs, R; Karimpour, S; Mielke, S; Montero, A; Rezvani, K; Savani, BN; Shenoy, A; Singh, A; Srinivasan, R, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Epstein, DJ | 1 |
| Liang, EC | 1 |
| Sharifi, H | 1 |
| Lai, YK | 1 |
| Arai, S | 1 |
| Graber-Naidich, A | 1 |
| Sundaram, V | 1 |
| Nelson, J | 1 |
| Hsu, JL | 1 |
| Savani, BN | 1 |
| Montero, A | 1 |
| Srinivasan, R | 1 |
| Singh, A | 1 |
| Shenoy, A | 1 |
| Mielke, S | 1 |
| Rezvani, K | 1 |
| Karimpour, S | 1 |
| Childs, R | 1 |
| Barrett, AJ | 1 |
| Chang, PM | 1 |
| Chiou, TJ | 1 |
| Yen, CC | 1 |
| Hsiao, LT | 1 |
| Liu, JH | 1 |
| Chen, PM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for Treatment of Bronchiolitis Obliterans Syndrome[NCT01287078] | Phase 2 | 25 participants (Actual) | Interventional | 2011-01-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with progressive disease at baseline with decline in FEV1 greater than 10% (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 2 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants with progressive disease at baseline with stablization of FEV1 (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 2 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants with stable disease at baseline with stablization in FEV1 and greater than 25% decline in systemic immunosuppression (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 3 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants who did not respond to treatment with cyclosporine inhalation solution (CIS) (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 7 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 2 |
Participants who responded to treatment with cyclosporine inhalation solution (CIS) (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 9 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants with stable disease at baseline with stablization of FEV1 and no change or increase in systemic immunosuppresion (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 4 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 2 |
Participants with stable or progressive disease at baseline with greater than 20% of decline in FEV1 (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 1 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants with stable or progressive disease at baseline with improvement of FEV1 (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 4 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
3 other studies available for carbon monoxide and Graft vs Host Disease
| Article | Year |
|---|---|
Epidemiology of Lower Respiratory Tract Infections and Community-Acquired Respiratory Viruses in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation: A Retrospective Cohort Study.
Topics: Adult; Bronchiolitis Obliterans; Carbon Monoxide; Graft vs Host Disease; Hematopoietic Stem Cell Tra | 2022 |
Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation.
Topics: Adolescent; Adult; Carbon Monoxide; Child; Chronic Disease; Comorbidity; Disease Progression; Female | 2006 |
Diffusion capacity predicts long-term survival after allogeneic bone marrow transplantation for acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Carbon Monoxide; Child; Female; Forced Expiratory Vo | 2008 |